{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:26:06Z","timestamp":1785878766414,"version":"3.56.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2010,9,13]],"date-time":"2010-09-13T00:00:00Z","timestamp":1284336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This randomized, double-blind, placebo-controlled, dose-response late phase 2 study evaluated the efficacy and safety of bazedoxifene in postmenopausal Japanese women 85 years of age or younger with osteoporosis. Eligible subjects received daily treatment with oral doses of bazedoxifene 20 or 40\u2009mg or placebo for 2 years. Efficacy assessments included bone mineral density (BMD) at the lumbar spine and other skeletal sites, bone turnover marker levels, lipid parameters, and incidence of new fractures. Of 429 randomized subjects, 387 were evaluable for efficacy, and 423 were included in the safety analyses (mean age, 64 years). At 2 years, the mean percent changes from baseline in lumbar spine BMD were significantly greater with bazedoxifene 20 and 40\u2009mg (2.43% and 2.74%, respectively) than with placebo (\u22120.65%, p\u2009&amp;lt;\u2009.001 for both). Both bazedoxifene doses significantly improved BMD at the total hip, femoral neck, and greater trochanter compared with placebo (p\u2009&amp;lt;\u2009.001 for all). Decreases in bone turnover markers were observed with bazedoxifene 20 and 40\u2009mg as early as 12 weeks (p\u2009&amp;lt;\u2009.05 for all) and were sustained throughout the study. Total and low-density lipoprotein cholesterol levels were significantly decreased from baseline with both bazedoxifene doses compared with placebo (p\u2009&amp;lt;\u2009.05 for all). Incidences of new vertebral and nonvertebral fractures were similar among the bazedoxifene and placebo groups. Overall, the incidence of adverse events with bazedoxifene 20 and 40\u2009mg was similar to that with placebo. Bazedoxifene significantly improved BMD, reduced bone turnover, and was well tolerated in postmenopausal Japanese women with osteoporosis. \u00a9 2011 American Society for Bone and Mineral Research.<\/jats:p>","DOI":"10.1002\/jbmr.252","type":"journal-article","created":{"date-parts":[[2010,9,13]],"date-time":"2010-09-13T19:25:31Z","timestamp":1284405931000},"page":"519-529","source":"Crossref","is-referenced-by-count":35,"title":["Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal japanese women with osteoporosis"],"prefix":"10.1093","volume":"26","author":[{"given":"Akira","family":"Itabashi","sequence":"first","affiliation":[{"name":"Saitama Center for Bone Research, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousei","family":"Yoh","sequence":"additional","affiliation":[{"name":"Hyogo College of Medicine, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkadi A","family":"Chines","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takami","family":"Miki","sequence":"additional","affiliation":[{"name":"Osaka City University Medical School, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Takada","sequence":"additional","affiliation":[{"name":"Shiga University of Medical Science, Shiga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Sato","sequence":"additional","affiliation":[{"name":"Tokyo Women's Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itsuo","family":"Gorai","sequence":"additional","affiliation":[{"name":"International University of Health and Welfare, Atami Hospital, Shizuoka, Japan, and Hori Maternity Hospital, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitsugu","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Shimane University Faculty of Medicine, Shimane, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Mizunuma","sequence":"additional","affiliation":[{"name":"Hirosaki University School of Medicine, Aomori, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ochi","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginger D","family":"Constantine","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Ohta","sequence":"additional","affiliation":[{"name":"Tokyo Women's Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2010,9,13]]},"reference":[{"key":"2024020318061259200_bib1","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/01.gme.0000222475.93345.b3","article-title":"Management of osteoporosis in postmenopausal women: 2006 position statement of the North American Menopause Society","volume":"13","author":"North American Menopause Society","year":"2006","journal-title":"Menopause."},{"key":"2024020318061259200_bib2","first-page":"21","article-title":"Osteoporotic fractures: mortality and quality of life","volume":"49","author":"Caliri","year":"2007","journal-title":"Panminerva Med."},{"key":"2024020318061259200_bib3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00002512-200724010-00003","article-title":"Patient adherence to osteoporosis medications: problems, consequences and management strategies","volume":"24","author":"Papaioannou","year":"2007","journal-title":"Drugs Aging."},{"key":"2024020318061259200_bib4","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s00774-006-0702-3","article-title":"Effect of raloxifene on clinical fractures in Asian women with postmenopausal osteoporosis","volume":"24","author":"Nakamura","year":"2006","journal-title":"J Bone Miner Metab."},{"key":"2024020318061259200_bib5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1359\/jbmr.071206","article-title":"Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-year results of a randomized, double-blind, placebo-, and active-controlled study","volume":"23","author":"Miller","year":"2008","journal-title":"J Bone Miner Res."},{"key":"2024020318061259200_bib6","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","article-title":"Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial","volume":"23","author":"Silverman","year":"2008","journal-title":"J Bone Miner Res."},{"key":"2024020318061259200_bib7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s007740170001","article-title":"Diagnostic criteria for primary osteoporosis: year 2000 revision","volume":"19","author":"Orimo","year":"2001","journal-title":"J Bone Miner Metab."},{"key":"2024020318061259200_bib8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1359\/jbmr.1999.14.1.90","article-title":"Defining incident vertebral deformity: a prospective comparison of several approaches","volume":"14","author":"Black","year":"1999","journal-title":"J Bone Miner Res."},{"key":"2024020318061259200_bib9","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J Bone Miner Res."},{"key":"2024020318061259200_bib10","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/jbmr.5650110716","article-title":"Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis","volume":"11","author":"Genant","year":"1996","journal-title":"J Bone Miner Res."},{"key":"2024020318061259200_bib11","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00198-003-1424-1","article-title":"Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial","volume":"14","author":"Morii","year":"2003","journal-title":"Osteoporos Int."},{"key":"2024020318061259200_bib12","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bone.2009.02.014","article-title":"Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX","volume":"44","author":"Kanis","year":"2009","journal-title":"Bone."},{"issue":"(Suppl 1)","key":"2024020318061259200_bib13","article-title":"Assessment of the effect of bazedoxifene on non-vertebral fracture risk","volume":"24","author":"McCloskey","year":"2009","journal-title":"J Bone Miner Res."},{"key":"2024020318061259200_bib14","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1517\/14656566.3.6.681","article-title":"The search for the ideal SERM","volume":"3","author":"Arun","year":"2002","journal-title":"Expert Opin Pharmacother."},{"key":"2024020318061259200_bib15","first-page":"558","article-title":"Adverse events reported by postmenopausal women in controlled trials with raloxifene","volume":"93","author":"Davies","year":"1999","journal-title":"Obstet Gynecol."},{"key":"2024020318061259200_bib16","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA."},{"key":"2024020318061259200_bib17","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/01.AOG.0000137349.79204.b8","article-title":"Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation","volume":"104","author":"Grady","year":"2004","journal-title":"Obstet Gynecol."},{"key":"2024020318061259200_bib18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0378-5122(01)00299-7","article-title":"The prevalence of menopausal symptoms in a community in Singapore","volume":"41","author":"Chim","year":"2002","journal-title":"Maturitas."},{"key":"2024020318061259200_bib19","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/humupd\/dmi018","article-title":"Culture and symptom reporting at menopause","volume":"11","author":"Melby","year":"2005","journal-title":"Hum Reprod Update."},{"issue":"(Suppl)","key":"2024020318061259200_bib20","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.amjmed.2005.09.048","article-title":"Strategies and issues for managing menopause-related symptoms in diverse populations: ethnic and racial diversity","volume":"118","author":"Rice","year":"2005","journal-title":"Am J Med."},{"key":"2024020318061259200_bib21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/13697130500499914","article-title":"Chinese women's symptoms: relation to menopause, age and related attitudes","volume":"9","author":"Shea","year":"2006","journal-title":"Climacteric."},{"key":"2024020318061259200_bib22","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/gme.0b013e3181a816be","article-title":"Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis","volume":"16","author":"Pinkerton","year":"2009","journal-title":"Menopause."},{"key":"2024020318061259200_bib23","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/gme.0b013e3181a818db","article-title":"Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women","volume":"16","author":"Archer","year":"2009","journal-title":"Menopause."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.252","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/26\/3\/519\/56559433\/252_ftp.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/26\/3\/519\/56559433\/252_ftp.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:54:10Z","timestamp":1710341650000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/26\/3\/519-529\/7598164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,13]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2010,9,13]]},"published-print":{"date-parts":[[2011,3,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.252","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,3,1]]},"published":{"date-parts":[[2010,9,13]]}}}